ESC 365 - JAK1/2 inhibitor ruxolitinib restores the responsiveness to hypoxia in pulmonary arterial hypertension-iPSC-derived endothelial cells

ESC Premium Access

JAK1/2 inhibitor ruxolitinib restores the responsiveness to hypoxia in pulmonary arterial hypertension-iPSC-derived endothelial cells

Session: Progress in the management of pulmonary hypertension

Topic: Chronic pulmonary hypertension

Speaker: Doctor M. Lachmann (Munich, DE)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Mark Johannes Lachmann

Rechts der Isar Hospital, Munich (Germany)

0 follower

9 more presentations in this session

Subcutaneous treprostinil for the treatment of non-operable chronic thromboembolic pulmonary hypertension: a randomized, controlled trial (CTREPH)

Speaker: Doctor R. Sadushi-Kolici (Vienna, AT)

A phase 3 study in an enriched population of pulmonary arterial hypertension patients with long term oxygen use demonstrating improved exercise tolerance with use of ambulatory inhaled nitric oxide

Speaker: Doctor H. Farber (Bollington, GB)

Comparative receptor pharmacology, pre-clinical efficacy and pharmacokinetics of a novel, next-generation prostacyclin receptor agonist, ralinepag (APD811), in humans and rats

Speaker: Doctor J. Adams (San Diego, US)

Cardiac magnetic resonance characterization of maladaptive right ventricular hypertrophy in chronic pulmonary hypertension.

Speaker: Doctor I. Garcia Lunar (Madrid, ES)

APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery

Speaker: Doctor J. Patel (London, GB)

Access the full session

Progress in the management of pulmonary hypertension

Speakers: Doctor M. Lachmann, Doctor R. Sadushi-Kolici, Doctor H. Farber, Doctor J. Adams, Doctor I. Garcia Lunar...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources